M. Cronk, R. Abraham, L. Perrin (2004)
Case report of a generalized seizure related to Paclitaxel infusion.Journal of the National Cancer Institute, 96 6
G. Bubley, M. Carducci, William Dahut, N. Dawson, D. Daliani, M. Eisenberger, W. Figg, B. Freidlin, S. Halabi, G. Hudes, M. Hussain, R. Kaplan, Charles Myers, W. Oh, D. Petrylak, Edward Reed, B. Roth, O. Sartor, H. Scher, J. Simons, V. Sinibaldi, E. Small, M. Smith, D. Trump, R. Vollmer, G. Wilding (1999)
Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 17 11
R. Ford, L. Schwartz, J. Dancey, L. Dodd, E. Eisenhauer, S. Gwyther, Lawrence Rubinstein, D. Sargent, L. Shankar, P. Therasse, J. Verweij (2009)
Lessons learned from independent central review.European journal of cancer, 45 2
J. Dancey, L. Dodd, R. Ford, R. Kaplan, M. Mooney, L. Rubinstein, L. Schwartz, L. Shankar, P. Therasse (2009)
Recommendations for the assessment of progression in randomised cancer treatment trials.European journal of cancer, 45 2
T. Barrett, P. Choyke, Hisataka Kobayashi (2006)
Imaging of the lymphatic system: new horizons.Contrast media & molecular imaging, 1 6
J. Goffin, Stefan Baral, D. Tu, D. Nomikos, L. Seymour (2005)
Objective Responses in Patients with Malignant Melanoma or Renal Cell Cancer in Early Clinical Studies Do Not Predict Regulatory ApprovalClinical Cancer Research, 11
C. Catalano, M. Francone, A. Ascarelli, Matteo Mangia, I. Iacucci, R. Passariello (2007)
Optimizing radiation dose and image qualityEuropean Radiology Supplements, 17
D. Sargent, Larry Rubinstein, Lawrence Schwartz, Janet Dancey, Constantine Gatsonis, Lori Dodd, L. Shankar (2009)
Validation of novel imaging methodologies for use as cancer clinical trial end-points.European journal of cancer, 45 2
M. Glabbeke, J. Verweij, I. Judson, O. Nielsen (2002)
Progression-free rate as the principal end-point for phase II trials in soft-tissue sarcomas.European journal of cancer, 38 4
G. Caviglia, Mario Rizzetto (1923)
TREATMENTThe Journal of Neurology and Psychopathology, s1-3
P. Therasse, E. Eisenhauer, J. Verweij (2006)
RECIST revisited: a review of validation studies on tumour assessment.European journal of cancer, 42 8
J. Bogaerts, R. Ford, D. Sargent, L. Schwartz, L. Rubinstein, D. Lacombe, E. Eisenhauer, J. Verweij, P. Therasse (2009)
Individual patient data analysis to assess modifications to the RECIST criteria.European journal of cancer, 45 2
F. Duffaud, P. Therasse (2000)
[New guidelines to evaluate the response to treatment in solid tumors].Bulletin du cancer, 87 12
I. Vergote, G. Rustin, E. Eisenhauer, G. Kristensen, E. Pujade-Lauraine, M. Parmar, M. Friedlander, A. Jakobsen, J. Vermorken (2000)
Re: new guidelines to evaluate the response to treatment in solid tumors [ovarian cancer]. Gynecologic Cancer Intergroup.Journal of the National Cancer Institute, 92 18
Joseph Baar, I. Tannock (1989)
Analyzing the same data in two ways: a demonstration model to illustrate the reporting and misreporting of clinical trials.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 7 7
K. Tonkin, D. Tritchler, I. Tannock (1985)
Criteria of tumor response used in clinical trials of chemotherapy.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 3 6
Appendix III – continued
Shankar (2006)
National Cancer Institute. Consensus recommendations for the use of 18F-FDG PET as an indicator of therapeutic response in patients in National Cancer Institute TrialsJ Nucl Med, 47
R. Low (2007)
Abdominal MRI advances in the detection of liver tumours and characterisation.The Lancet. Oncology, 8 6
P. Taylor, D. Haverstick (2005)
Re: New guidelines to evaluate the response to treatment in solid tumors (ovarian cancer).Journal of the National Cancer Institute, 97 2
D. MacDonald, T. Cascino, S. Schold, J. Cairncross, G. Cairncross (1990)
Response criteria for phase II studies of supratentorial malignant glioma.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 8 7
M. Paesmans, J. Sculier, P. Libert, G. Bureau, G. Dabouis, J. Thiriaux, J. Michel, O. Cutsem, R. Sergysels, P. Mommen, J. Klastersky (1997)
Response to chemotherapy has predictive value for further survival of patients with advanced non-small cell lung cancer: 10 years experience of the European Lung Cancer Working Party.European journal of cancer, 33 14
H. Scher, S. Halabi, I. Tannock, M. Morris, C. Sternberg, M. Carducci, M. Eisenberger, C. Higano, G. Bubley, R. Dreicer, D. Petrylak, P. Kantoff, E. Basch, W. Kelly, W. Figg, E. Small, T. Beer, G. Wilding, Alison Martin, M. Hussain (2008)
Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 26 7
M. Buyse, P. Thirion, R. Carlson, T. Burzykowski, G. Molenberghs, P. Piedbois (2000)
Relation between tumour response to first-line chemotherapy and survival in advanced colorectal cancer: a meta-analysisThe Lancet, 356
Rustin (2004)
Re: New guidelines to evaluate the response to treatment in solid tumors (ovarian cancer)J Natl Cancer Inst, 96
T. Walsh (1969)
Reporting results.Archives of otolaryngology, 90 2
B. Cheson, B. Pfistner, M. Juweid, R. Gascoyne, L. Specht, S. Horning, B. Coiffier, R. Fisher, A. Hagenbeek, E. Zucca, S. Rosen, S. Stroobants, T. Lister, R. Hoppe, M. Dreyling, K. Tobinai, J. Vose, J. Connors, M. Federico, V. Diehl (2007)
Revised response criteria for malignant lymphoma.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 25 5
L. Schwartz, J. Bogaerts, R. Ford, L. Shankar, P. Therasse, S. Gwyther, E. Eisenhauer (2009)
Evaluation of lymph nodes with RECIST 1.1.European journal of cancer, 45 2
P. Therasse, S. Arbuck, E. Eisenhauer, J. Wanders, R. Kaplan, L. Rubinstein, J. Verweij, M. Glabbeke, A. Oosterom, M. Christian, S. Gwyther (2000)
New guidelines to evaluate the response to treatment in solid tumorsBreast Cancer, 12
C. Moskowitz, X. Jia, L. Schwartz, M. Gönen (2009)
A simulation study to evaluate the impact of the number of lesions measured on response assessment.European journal of cancer, 45 2
A. Miller, B. Hoogstraten, M. Staquet, A. Winkler (1981)
Reporting results of cancer treatmentCancer, 47
R. El-Maraghi, E. Eisenhauer (2008)
Review of phase II trial designs used in studies of molecular targeted agents: outcomes and predictors of success in phase III.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 26 8
L. Shankar, J. Hoffman, S. Bacharach, M. Graham, J. Karp, A. Lammertsma, S. Larson, D. Mankoff, B. Siegel, A. Abbeele, J. Yap, D. Sullivan (2006)
Consensus recommendations for the use of 18F-FDG PET as an indicator of therapeutic response in patients in National Cancer Institute Trials.Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 47 6
European Journal of Cancer – Pubmed
Published: Feb 3, 2009
Access the full text.
Sign up today, get DeepDyve free for 14 days.